论文部分内容阅读
目的 :比较泮托拉唑与奥美拉唑两周疗法治疗慢性胃炎伴糜烂的临床疗效及安全性。方法 :10 0例经胃镜证实为慢性胃炎伴糜烂患者 ,随机入选泮托拉唑 (A组 )与奥美拉唑 (B组 )治疗组 ,每组 5 0例。A与B两组分别被给予泮托拉唑 4 0mgqd× 14d及奥美拉唑 2 0mgqd× 14d ,如幽门螺杆菌 (Hp)阳性再加克拉霉素 2 5 0mgbid× 7d和替硝唑 5 0 0mgbid× 7d。比较两组的疗效及不良反应。结果 :A与B组总疗效分别为 93.6 %及 97.8% ,疗效无显著差异 (P >0 .0 5 ) ;A组两周治疗疼痛总有效率 (93.6 % )与B组 (97.8% )相似 ;Hp根除率A组 (88.2 % )和B组 (85 .7% )之间无显著性差异 ;每组各有 10例复查胃镜 ,糜烂消失各为 7例和 8例 ;两组不良反应发生率无显著性差异。结论 :泮托拉唑与奥美拉唑相比 ,对慢性胃炎伴糜烂具有同样的有效性和安全性。
Objective: To compare the clinical efficacy and safety of two-week therapy with pantoprazole and omeprazole in the treatment of chronic gastritis with erosion. Methods: One hundred and ten patients with chronic gastritis and erosion were confirmed by gastroscopy. Patients were randomly assigned to receive pantoprazole (group A) and omeprazole (group B), with 50 cases in each group. A and B were given pantoprazole 4 0mgqd × 14d and omeprazole 2 0mgqd × 14d, such as H. pylori (Hp) positive plus clarithromycin 250mgbid × 7d and tinidazole 50 0mgbid × 7d. The curative effect and adverse reaction of the two groups were compared. Results: The total effective rates in group A and group B were 93.6% and 97.8%, respectively, with no significant difference (P> 0.05). The total effective rate of two weeks in group A (93.6%) was similar to that in group B (97.8%) ; There was no significant difference between Hp eradication rate in group A (88.2%) and group B (85.7%); there were 10 cases in each group and 7 cases disappeared in each group, and 8 cases disappeared in each group. Adverse reactions occurred in both groups No significant difference in rates. Conclusion: Pantoprazole has the same efficacy and safety as chronic oesophagitis with erosion compared with omeprazole.